Notts, United Kingdom

Joe Wrigglesworth



Average Co-Inventor Count = 15.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Notts, GB (2016 - 2019)
  • Nottingham, GB (2023)

Company Filing History:


Years Active: 2016-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Joe Wrigglesworth: Innovator in Carboxamide Derivatives

Introduction

Joe Wrigglesworth is a notable inventor based in Notts, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of carboxamide derivatives. With a total of 3 patents to his name, Wrigglesworth continues to push the boundaries of innovation in his area of expertise.

Latest Patents

Wrigglesworth's latest patents focus on carboxamide derivatives. The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, along with a method for manufacturing these compounds and their therapeutic uses. Additionally, the invention includes a combination of pharmacologically active agents and a pharmaceutical composition, showcasing the potential applications of his work in medical treatments.

Career Highlights

Wrigglesworth is currently employed at Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other experts in the field and contribute to groundbreaking research and development projects. His work has been instrumental in advancing the understanding and application of carboxamide derivatives in pharmaceuticals.

Collaborations

Some of Wrigglesworth's coworkers include Kamlesh Jagdis Bala and Andrew Brearley. Their collaboration fosters a dynamic environment for innovation and enhances the potential for successful outcomes in their projects.

Conclusion

Joe Wrigglesworth is a dedicated inventor whose work in carboxamide derivatives has the potential to impact the pharmaceutical industry significantly. His contributions, along with his collaborations at Novartis AG, highlight the importance of innovation in developing new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…